Skip to content

Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study

Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01806532
Enrollment
10
Registered
2013-03-07
Start date
2008-01-31
Completion date
2019-03-31
Last updated
2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Keywords

computed tomography and positron emission tomography, respiration, artificial, respiratory distress syndrome, adult

Brief summary

The goal of this study is to investigate acute respiratory distress syndrome (ARDS) and septic lung with positron emission tomography (PET) imaging and to examine the distribution of inflammation, as measured by neutrophil metabolic activity.

Interventions

None listed

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Group 1 * Mechanically ventilated patients scheduled to undergo a CT scanning for their routine clinical care * More than 24 hours of mechanical ventilation * Less than 15 days of mechanical ventilation if patient presents ALI/ARDS (in order to exclude the late, fibrotic, stage of ARDS) Group 2 * Mechanically ventilated patients with a diagnosis of sepsis * Less than 96 hours of mechanical ventilation

Exclusion criteria

* Age less than 18 years * Hemodynamic instability, defined as: systolic blood pressure (SBP) \< 90 mmHg that is not adequately stabilized by vasopressors or inotropic agents. For these purposes, SBP will not be considered adequately stabilized if the dose of the vasopressor/inotrope has not been stable for at least one hour * Hypoxemia, defined as: PaO2 \< 70 mmHg on an inspired oxygen fraction (FiO2) greater than or equal to 0.9; FiO2 greater than or equal to 0.8 at baseline * Hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3), that develop when the patient is mobilized during routine nursing care such as repositioning/washing the patient or changing their bed linens * Hemodynamic and/or respiratory instability (as defined, respectively, in 2 and 3), that develop when a 15-25 second respiratory pause is introduced as per the study protocol. This will be tested by inducing such a pause prior to transporting the patient * Patients must be deemed by the treating clinical staff to be able to tolerate leaving the ICU for 90 minutes (40-60 minute imaging time + 30 minute safety margin). Treating MD, RT, and RN must all agree that the patient is stable for transport * Any acute or chronic condition which, in the opinion of the investigator, might confound the imaging measurements (such as, but not limited to, severe bronchospasm, pulmonary infection, and lung tumor) * Air leaks requiring tube thoracostomy (e.g., pneumothorax, bronchopleural fistula) * Pregnancy (since this is a study which would expose a fetus to radiation risk) * Patients who have neither an arterial nor a central venous line at the time of the enrollement

Design outcomes

Primary

MeasureTime frameDescription
Regional 18F-FDG activityDay of imaging.Each patient will undergo PET-CT scans and the regional 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) activity will be measured. This is a measure of regional neutrophil metabolic activity and is used to assess inflammation in the lung. The degree of inflammation will be related to the regional expansion of the lung, as measured by CT scan.

Countries

United States

Contacts

Primary ContactMarcos Vidal Melo, MD, PhD
VidalMelo.Marcos@mgh.harvard.edu617-726-8980

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026